ArQule, Inc. to Report Third Quarter 2009 Financial Results on Thursday, November 5, 2009.Conference call and web cast scheduled for 9:00 a.m. eastern time WOBURN, Mass. -- ArQule, Inc. (NASDAQ NASDAQ in full National Association of Securities Dealers Automated Quotations U.S. market for over-the-counter securities. Established in 1971 by the National Association of Securities Dealers (NASD), NASDAQ is an automated quotation system that reports on : ARQL) today announced that it will report its financial results for the third quarter of 2009 in a press release to be issued on Thursday, November 5, 2009 at 7:00 a.m. eastern time. The Company will host a conference call and web cast to discuss these results at 9:00 a.m. eastern time on that day. Conference call details Date: > > > > > > > Thursday, November 5, 2009 Time: > > > > > > > 9:00 a.m. ET Conference Call Numbers > > > > > > > Domestic: > > > > > > > 866-770-7125 International: > > > > > > > 617-213-8066 Participant Passcode: > > > > > > > 76724058 Web cast: > > > > > > > http://www.arqule.com A replay of the conference call will be available beginning at 12:00 p.m. on November 5, 2009 for seven days and can be accessed by dialing toll-free 888-286-8010 and outside the U.S. 1-617-801-6888. The access code is 86035092. About ArQule ArQule is a biotechnology company engaged in the research and development of next-generation, small-molecule cancer therapeutics. The Company's targeted, broad-spectrum products and research programs are focused on key biological processes that are central to cancer. ArQule's lead product, in Phase 2 clinical development, is ARQ 197, an inhibitor of the c-MET receptor tyrosine kinase Receptor tyrosine kinases (RTK)s are the high affinity cell surface receptors for many polypeptide growth factors, cytokines and hormones. Of the ninety unique tyrosine kinase genes idenitified in the human genome, 58 encode receptor tyrosine kinase proteins. . The Company has also initiated Phase 1 clinical testing with ARQ 621, designed to inhibit the Eg5 kinesin motor protein. An additional clinical-stage program includes compounds that activate the cell's DNA DNA: see nucleic acid. DNA or deoxyribonucleic acid One of two types of nucleic acid (the other is RNA); a complex organic compound found in all living cells and many viruses. It is the chemical substance of genes. damage response mechanism mediated by the E2F-1 transcription factor. The Company's pre-clinical pipeline includes a compound designed to inhibit the BRAF BRAF Baton Rouge Area Foundation BRAF Bookstore Requisition Attachment Form (USF) kinase. ArQule's current discovery efforts, which are based on the ArQule Kinase Inhibitor Platform (AKIP AKIP A-Kinase-Interacting Protein (also seen as Aurora-A Kinase Interacting Protein) [TM]) are focused on the identification of novel kinase inhibitors that are potent, selective and do not compete with ATP ATP: see adenosine triphosphate. ATP in full adenosine triphosphate Organic compound, substrate in many enzyme-catalyzed reactions (see catalysis) in the cells of animals, plants, and microorganisms. (adenosine triphosphate triphosphate /tri·phos·phate/ (tri-fos´fat) a salt containing three phosphate radicals. tri·phos·phate n. A salt or ester containing three phosphate groups. ) for binding to the kinase. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion